Antibody. Regeneron may terminate this Agreement with respect to the entire Territory for IL-1 Antibody Products, on (i) nine (9) months' written notice to Novartis at any time prior to the first Launch of such IL-1 Antibody Product in the IL-1 Antibody Territory; and (ii) twelve (12) months' written notice to Novartis at any time after the first Launch of such IL-1 Antibody Product in the IL-1 Antibody Territory. Except as otherwise provided below in this Section 19.4(b), the Agreement shall continue in full force and effect with respect to the IL-1 Antibody Product through the applicable notice period set forth above (the "IL-1 Antibody Termination Notice Period"), provided that Regeneron shall not be required to pay to Novartis any milestone payment in respect of the IL-1 Antibody Product which is achieved during the IL-1
Appears in 2 contracts
Sources: Collaboration, License and Option Agreement, Collaboration, License and Option Agreement (Regeneron Pharmaceuticals Inc)